{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:21:02Z","timestamp":1773829262320,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"publisher","award":["IG20583"],"award-info":[{"award-number":["IG20583"]}],"id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["MFAG25149"],"award-info":[{"award-number":["MFAG25149"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clbc.2025.02.016","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:26:14Z","timestamp":1741220774000},"page":"431-443.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study"],"prefix":"10.1016","volume":"25","author":[{"given":"Giovanna","family":"Garufi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1853-4927","authenticated-orcid":false,"given":"Luca","family":"Mastrantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1310-6115","authenticated-orcid":false,"given":"Noemi","family":"Maliziola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Di Monte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Arcuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Frescura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelachiara","family":"Rotondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Paris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Marazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-3395","authenticated-orcid":false,"given":"Gianluca","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Carbognin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2025.02.016_bib0001","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2025.02.016_bib0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/PAP.0000000000000232","article-title":"Molecular classification of breast cancer","volume":"27","author":"Tsang","year":"2020","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0003","first-page":"106","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2025.02.016_bib0004","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2025.02.016_bib0006","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0007","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0008","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.clbc.2019.07.013","article-title":"Hormone receptor and Human epidermal growth factor receptor 2 detection in invasive breast carcinoma: A retrospective study of 12,467 patients from 19 Chinese representative clinical centers","volume":"20","author":"Shui","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2025.02.016_bib0009","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology Phase III randomized trial comparing adjuvant chemotherapy with or without Trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0010","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.2009.24.1661","volume":"28","author":"Gianni","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0011","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.clbc.2025.02.016_bib0012","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0013","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.02.016_bib0014","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of Trastuzumab Deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.02.016_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31170","article-title":"Comparison of management and outcomes in ERBB2-low vs ERBB2-zero metastatic breast cancer in France","volume":"5","author":"de Calbiac","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clbc.2025.02.016_bib0018","doi-asserted-by":"crossref","first-page":"774577","DOI":"10.3389\/fonc.2021.774577","article-title":"In real life, low-level HER2 expression may Be associated with better outcome in HER2-negative breast Cancer: a study of the National Cancer Center, China","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0019","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13058-021-01492-x","article-title":"Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry","volume":"23","author":"Gampenrieder","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2025.02.016_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.06.033","article-title":"Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status","volume":"155","author":"Hein","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2025.02.016_bib0021","first-page":"1177","article-title":"Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer","volume":"8","author":"Tarantino","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0022","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12282-021-01303-3","article-title":"The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status","volume":"29","author":"Horisawa","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2025.02.016_bib0023","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1634\/theoncologist.2012-0194","article-title":"Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer","volume":"17","author":"Rossi","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2025.02.016_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41523-025-00727-w","article-title":"Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy","volume":"11","author":"Mastrantoni","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2025.02.016_bib0025","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2025.02.016_bib0026","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JOP.18.00206","article-title":"HER2 Testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical practice guideline focused update summary","volume":"14","author":"Wolff","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clbc.2025.02.016_bib0027","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0028","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2025.02.016_bib0029","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1200\/JCO.23.00435","article-title":"Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials","volume":"41","author":"Litton","year":"2023","journal-title":"NeoSTEEP. J Clin Oncol."},{"key":"10.1016\/j.clbc.2025.02.016_bib0030","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.2010.31.8469","article-title":"Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy","volume":"29","author":"Mittendorf","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0031","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s10549-011-1488-0","article-title":"Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics","volume":"131","author":"Lips","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.02.016_bib0032","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","article-title":"Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007","volume":"18","author":"Goldhirsch","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0033","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","article-title":"Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.clbc.2025.02.016_bib0034","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.1999.17.10.3033","article-title":"Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group","volume":"17","author":"Miller","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0035","first-page":"34a","article-title":"Dose-dense sequential epiru- bicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study","volume":"20","author":"Untch","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0036","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","article-title":"Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy","volume":"170","author":"Haque","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.02.016_bib0037","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2022.08.031","article-title":"Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy","volume":"176","author":"Kang","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2025.02.016_bib0038","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejca.2022.09.017","article-title":"Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers","volume":"176","author":"de Nonneville","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2025.02.016_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2022.12.006","article-title":"Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer","volume":"67","author":"Zhou","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2025.02.016_bib0040","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1245\/s10434-022-12369-4","article-title":"Clinical, pathological complete response, and prognosis characteristics of HER2-low breast cancer in the neoadjuvant chemotherapy setting: A retrospective analysis","volume":"29","author":"Shao","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0041","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-021-06365-7","article-title":"HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer","volume":"190","author":"de Moura Leite","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.02.016_bib0042","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12282-022-01431-4","article-title":"HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC","volume":"30","author":"Li","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2025.02.016_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2023.152125","article-title":"Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer","volume":"64","author":"Qiao","year":"2023","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0044","doi-asserted-by":"crossref","first-page":"996434","DOI":"10.3389\/fmolb.2022.996434","article-title":"Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world","volume":"9","author":"Di Cosimo","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.clbc.2025.02.016_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112824","article-title":"HER2-Low breast cancer: molecular characteristics and prognosis","volume":"13","author":"Agostinetto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2025.02.016_bib0046","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41523-022-00434-w","article-title":"HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment","volume":"8","author":"Miglietta","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2025.02.016_bib0047","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clbc.2025.02.016_bib0048","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0049","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.critrevonc.2017.10.001","article-title":"Advances in the management of HER2-positive early breast cancer","volume":"119","author":"Baselga","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0050","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1158\/1078-0432.CCR-14-2728","article-title":"Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy","volume":"21","author":"Giuliano","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2025.02.016_bib0051","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1158\/0008-5472.CAN-07-2707","article-title":"Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function","volume":"68","author":"Massarweh","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2025.02.016_bib0052","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF01961241","article-title":"Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2\/neu","volume":"24","author":"Benz","year":"1992","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.02.016_bib0053","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2015.09.022","article-title":"Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy","volume":"53","author":"Marme","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2025.02.016_bib0054","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1200\/JCO.2011.38.3174","article-title":"Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system","volume":"29","author":"Yi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0055","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1200\/JCO.2007.11.5352","article-title":"Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy","volume":"26","author":"Jeruss","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0056","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221138657","article-title":"Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy","volume":"15","author":"Garufi","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0057","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10549-018-4730-1","article-title":"Assessment of the predictive role of pretreatment ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients","volume":"170","author":"Chen","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2025.02.016_bib0058","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jjco\/hyz012","article-title":"Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"49","author":"Jain","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0059","doi-asserted-by":"crossref","first-page":"GS2","DOI":"10.1158\/1538-7445.SABCS22-GS2-03","article-title":"Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer","volume":"83","author":"Bardia","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2025.02.016_bib0060","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1634\/theoncologist.8-4-307","article-title":"The her-2\/neu gene and protein in breast cancer 2003: biomarker and target of therapy","volume":"8","author":"Ross","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2025.02.016_bib0061","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ajcp\/aqab117","article-title":"HER2-Low breast cancers","volume":"157","author":"Zhang","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0062","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/dmd.119.089276","article-title":"Evaluation of quantitative relationship between target expression and antibody-drug conjugate exposure inside cancer cells","volume":"48","author":"Sharma","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clbc.2025.02.016_bib0063","doi-asserted-by":"crossref","first-page":"D8","DOI":"10.1158\/1538-7445.SABCS21-PD8-02","article-title":"Abstract PD8-02: trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY)","volume":"82","author":"Di\u00e9ras","year":"2022","journal-title":"Cancer Research"},{"key":"10.1016\/j.clbc.2025.02.016_bib0064","doi-asserted-by":"crossref","first-page":"11S35","DOI":"10.1016\/S0007-4551(21)00635-4","volume":"108","author":"Garberis","year":"2021","journal-title":"Bull Cancer"},{"key":"10.1016\/j.clbc.2025.02.016_bib0065","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1016\/j.csbj.2021.07.003","article-title":"Machine learning in the prediction of cancer therapy","volume":"19","author":"Rafique","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.clbc.2025.02.016_bib0066","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.02.016_bib0067","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B trial","volume":"39","author":"Loibl","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0068","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/modpathol.3880440","article-title":"HER-2\/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization","volume":"14","author":"Thomson","year":"2001","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2025.02.016_bib0069","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1309\/AJCP4A7KTAYHZSOE","article-title":"Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance","volume":"140","author":"Lambein","year":"2013","journal-title":"Am J Clin Pathol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925000461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925000461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T01:41:52Z","timestamp":1750383712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925000461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1526820925000461"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.02.016","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}